This study analyzed the long-term effect of behavioral counseling on increasing daily physical activity (PA) and reducing sedentary (SED) time on changes in beta-cell (β-cell) function and glucose control in patients with type 2 diabetes (T2D). The authors concluded that increasing moderate-to-vigorous-intensity physical activity (MVPA) and reducing SED time can effectively preserve the β-cell function of the pancreas and improve glucose control in these patients.

This study evaluated the effectiveness and safety of the combination of trifluridine-tipiracil (Lonsurf) and bevacizumab (Avastin) in patients with unresponsive (refractory) metastatic colorectal cancer (mCRC) in a real-world setting. The main finding was that trifluridine-tipiracil plus bevacizumab was safe and effective in patients with mCRC in a real-world setting.

This study compared the long-term outcomes of percutaneous coronary intervention (PCI) using everolimus (Afinitor)-eluting stents (Xience) versus coronary artery bypass grafting (CABG) in patients with multivessel coronary artery disease (CAD). The data showed that both treatments were associated with a similar risk of heart attack, stroke, and death over the long term in these patients. However, PCI increased spontaneous heart attacks and repeat revascularization compared to CABG in these patients.

This study evaluated which sequence of treatment should be given first - immunotherapy or targeted therapy - for the most clinical benefit in patients with BRAF-mutated metastatic melanoma. The data showed that immunotherapy followed by targeted therapy significantly improved survival outcomes in these patients.

The study compared the effectiveness of darolutamide (Nubeqa), apalutamide (Erleada), and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that darolutamide, apalutamide, and enzalutamide were similarly effective and improved survival outcomes compared to placebo in men with nmCRPC.

This study investigated the safety and effectiveness of different doses of asundexian (BAY 2433334) in patients with acute myocardial infarction (MI; heart attack) treated with dual antiplatelet therapy (DAPT). The data showed that asundexian 50 mg when added to DAPT inhibits blood clotting factor XIa by more than 90% without significantly increasing the risk of bleeding in these patients.

This study investigated the safety and effectiveness of ibrutinib (Imbruvica) lead-in treatment before venetoclax (Venclexta) initiation for reducing tumor size in patients with chronic lymphocytic leukemia (CLL). The data showed that three cycles of ibrutinib lead-in treatment before venetoclax initiation significantly reduced the tumor size, decreased the risk of tumor lysis syndrome (TLS), and reduced the need for hospitalization for intensive monitoring for TLS in these patients.

This study investigated the occurrence of osteoporosis (OP) in patients with rheumatoid arthritis (RA). The authors concluded that although significant advancements were made in OP prevention, treatment and diagnosis, a high occurrence was still observed in patients with RA.

This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients.

This study evaluated the effectiveness and safety of combinations of anti-depressive medication for the treatment of diabetic peripheral neuropathic pain (DPNP) in patients with diabetes. The study showed that combination treatment improved pain in these patients and was well tolerated.